1   SH20028

2   C. O'Connor *et al.*

3   ART adherence among MSM in Manila, Philippines

4   **Risk factors affecting adherence to antiretroviral therapy among HIV patients in**
5   **Manila, Philippines: a baseline cross-sectional analysis of the Philippines Connect for**
6   **Life Study**

7   *Cara O'Connor*[A,B,C,H], *Katerina Leyritana*[A], *Kris Calica*[A], *Randeep Gill*[D], *Aoife M. Doyle*[B], *James J. Lewis*[E] and
8   *Edsel Maurice Salvaña*[F,G]

9   [A]Sustained Health Initiatives of the Philippines (SHIP), Mandaluyong, Philippines.

10 [B]London School of Hygiene and Tropical Medicine, London, UK.

11 [C]Wits Reproductive Health and HIV Research Institute, Johannesburg, South Africa.

12 [D]Johnson & Johnson Global Public Health, London, UK.

13 [E]Y Lab, The Public Services Innovation Lab for Wales, School of Social Sciences, Cardiff University,
14 UK.

15 [F]Institute of Molecular Biology and Biotechnology, National Institutes of Health, University of the
16 Philippines Manila, Ermita, Philippines.

17 [G]Section of Infectious Disease, Department of Medicine, University of the Philippines College of
18 Medicine, University of the Philippines Manila, Ermita, Philippines.

19 [H]Corresponding author. Email: coconnor@ship.ph

20 *Background*: The Philippines HIV epidemic is one of the fastest growing, globally. Infections among men who
21 have sex with men (MSM) are rising at an alarming rate, necessitating targeted evidence-based interventions to
22 reach epidemic control. Treatment as prevention is a key strategy to end AIDS, making it a priority to explore
23 novel approaches to retain people living with HIV (PLHIV) in care, support adherence, and reach viral
24 suppression. *Methods*: This cross-sectional analysis describes HIV-related risk behaviours and adherence to
25 antiretroviral therapy (ART) in a population of HIV-positive patients at a clinic in Metro Manila, Philippines
26 participating in the Philippines Connect for Life[TM] cohort study. *Results*: Among 426 HIV-positive adults
27 taking ART, 79% reported ≥95% adherence over the prior 30 days. Longer time on treatment was associated
28 with reduced adherence to ART (adjusted odds ratio (AOR) = 0.87 per year, $P = 0.027$). Being in a
29 serodiscordant relationship, in which the subject's primary partner was HIV negative, increased adherence
30 (AOR = 3.19, $P = 0.006$). Inconsistent condom use (AOR = 0.50, $P = 0.103$) and injection drug use (AOR =
31 0.54, $P = 0.090$) are potentially associated with reduced adherence to ART. Patients used drugs and alcohol at
32 significantly higher rates than the general population. *Conclusions*: The study found that patients in this setting
33 require intervention to address treatment fatigue. Interventions to improve social support of PLHIV, as well as

34 harm-reduction approaches for drug and alcohol use, could improve adherence in this population, strengthening

35 the test-and-treat strategy to control the epidemic.

36 **Keywords:** adherence, antiretroviral therapy, Asia, evidence-based policy, harm reduction, HIV/AIDS, men

37 who have sex with men, people living with HIV, Philippines.

38 We conducted a study in the Philippines, where the HIV/AIDS epidemic is concentrated among young men who

39 have sex with men (MSM), to better understand adherence to antiretroviral therapy (ART) among this key

40 population. In our study population of 462 HIV-positive patients, predominantly young MSM, 79% of patients

41 were adherent to their ART. We found that longer time on treatment led to lower adherence, and that social

42 support and substance use were important factors.

43 **Introduction**

44 The Philippines has the fastest growing HIV/AIDS epidemic in the Asia−Pacific region.[1−3] National

45 surveillance data show that the number of new HIV cases in the Philippines has risen at an alarming

46 rate during the past decade, with an increase from 311 cases identified in 2007 to 11 427 cases

47 identified in 2018 – a 36-fold increase in new HIV diagnoses.[4] According to the Joint United Nations

48 Programme on HIV/AIDS (UNAIDS)'s surveillance reports, the Philippines' progress towards

49 reaching HIV/AIDS 90–90–90 goals is slow, with 67% of people living with HIV (PLHIV) aware of

50 their status, 48% of those who know their status on treatment, and low coverage of viral load testing

51 (<50%).[5]

52 Young men who have sex with men (MSM) are the key population in this emerging epidemic.

53 Early in the HIV epidemic, most diagnoses were among heterosexual females, especially sex workers.

54 Today, 85% of new cases are in MSM, the median age of new cases in the Philippines is 28 years, and

55 more than 80% of people living with HIV/AIDS in the Philippines are aged under 35 years.[4] In 2015,

56 a national surveillance survey found that HIV prevalence among MSM who practice anal sex was 6%,

57 an increase from 3.3% in 2013.[6−8]

58 As the burden of HIV increases, it is imperative that as many HIV-infected people as possible are

59 diagnosed, started on treatment and successfully retained in care. Achieving adequate viral

60 suppression through the use of antiretroviral therapy (ART) will be one of the key tools in ending the

61 HIV epidemic in the Philippines. Unfortunately, widespread stigma, lack of knowledge, and barriers

62 to accessing care pose a challenge to engaging patients in testing and then ensuring high levels of

63 adherence to ART and retention in care.[6,8,9] As in many developing countries, high rates of first-line

64 treatment failure, loss to follow up, and suboptimal treatment adherence lead to poor outcomes for

65 many HIV patients in the Philippines.[10,11]

66 Evidence-based public health interventions are needed. However, a 2015 report by the World

67 Health Organization (WHO) highlights that the body of HIV research conducted in the Philippines

68 has been limited,[12] and a systematic review of the HIV risk studies in the Philippines through April

69 2018 found only three publications that included data about the group most affected by HIV, MSM.[13]

70 This study aims to describe the demographic profile, clinical characteristics, HIV-related risk

71 behaviours, quality of life (QOL), and ART adherence levels in a population of HIV-positive

72 individuals comprised primarily of MSM receiving treatment at the Sustained Health Initiatives of the

73 Philippines (SHIP) Clinic in Metro Manila, Philippines.

74 **Methods**

75 *Study design, participants, and setting*

76 A cross-sectional analysis was conducted using data from the baseline visit of a cohort study of

77 patients at the SHIP clinic. The purpose of the larger cohort study was to evaluate the Connect for

78 Life™ mobile phone adherence support intervention. Data were collected from October 2016 to

79 December 2018.

80 The SHIP Clinic is a public–private partnership, low-cost, fee-for-service facility in Mandaluyong,

81 Metro Manila, which has provided HIV treatment and a comprehensive package of primary healthcare

82 services to more than 900 patients since it opened in 2012. SHIP is a satellite partner clinic of the

83 STI/AIDS Guidance Intervention & Prevention Unit at the Philippine General Hospital.

84 All patients starting or continuing on ART at the SHIP clinic who had a mobile phone and who

85 spoke English (one of the two official languages in the Philippines and spoken fluently by nearly all

86 of the patients from the study site) were eligible to participate in the study. Mobile phones were

87 required because all patients who were enrolled would receive a mobile phone adherence intervention.

88 The study coordinator approached patients during their routine clinic visits to provide information

89 about the study and complete the informed consent process.

90 *Measures*

91 At the baseline study visit, the study coordinator collected demographic data and extracted medical

92 history from the patient charts. Each participant completed a questionnaire on HIV-related

93 knowledge, attitudes and practices (KAP) that was specific to the mobile phone adherence

94 intervention and the WHO HIV Quality of Life questionnaire (WHO QOL-HIV BREF

95 https://www.who.int/mental_health/publications/whoqol_hiv_bref.pdf). Patients who had taken ART

96 before also completed an adherence questionnaire that was adapted from the AIDS Clinical Trials

97 Group tools. All questionnaires were in English. The questionnaires were self-administered, with

98 assistance from the study coordinator as requested.

99 The self-reported adherence measure used a visual analogue scale (VAS) in which patients reported

100 the proportion of ART doses taken in the prior 30 days from 0–100%. For ART to be effective, it

101 should be taken consistently, and early studies reported that ≥95% adherence to ART was required to

102   achieve and maintain viral suppression.[14,15] More recent studies have shown that virological

103   suppression may be achieved with adherence levels <95%; however, this is dependent on the duration

104   of treatment and the ART regimen.[16–18] Therefore, in this analysis, those who took ≥95% of their ART

105   doses were considered adherent, and <95% as non-adherent.

106   *Statistical analysis*

107   Descriptive data analysis was conducted to categorise the study population. Categorical variables

108   were described with proportions and continuous variables were described with means and confidence

109   intervals. We examined which characteristics of individuals were associated with adherence to ART

110   of >95%. Crude odds ratios (ORs) were calculated with logistic regression to examine which

111   demographic, behavioural, and clinical factors are related to self-reported adherence. Factors

112   significant at *P*-value <0.1 on univariate analysis were included in a multivariate logistic regression

113   analysis. Clinical variables were excluded from the multivariate if there was plausible reverse

114   causality between ART adherence and the clinical characteristics (i.e. viral load suppression). Where

115   possible, continuous variables were used in the multivariate model, whereas categorical variables

116   were used for illustrative purposes in the crude OR descriptive analyses. Data analysis was conducted

117   in Stata 15 (StataCorp LLC).

118   *Ethics*

119   Ethical clearance was obtained from the University of the Philippines Manila Research Ethics

120   Board (protocol number 2016–265–01) and from the London School of Hygiene and Tropical

121   Medicine (reference number 11631). All patients provided written consent before inclusion in the

122   study.

123   **Results**

124   The cross-sectional analysis included 426 individuals. Variables were included in the following

125   categories: Demographics, Clinical Characteristics, HIV Knowledge, Risk Behaviours, QOL,

126   Adherence/Reasons for Missing Medication.

127   At the time study enrolment began, the clinic had ~600 active patients. The study coordinator

128   screened 485 patients as they presented during routine clinic visits, of whom 483 were eligible to

129   participate in the study (one did not speak English, one did not have a Philippine mobile phone), and

130   462 patients provided consent and were enrolled (of the 21 who declined, the most common reason

131   was that they did not want to receive calls or SMS related to the intervention). Of 462 people enrolled

132   in the Connect for Life intervention study, 31 were either ineligible to fill out the adherence

133   questionnaire (initiated ART at the study baseline visit and had not started taking pills) or had missing

134   questionnaires; as a result 426 individuals reported ART adherence, and are included in this analysis.

135   All but one of these 426 subjects were male (99.8%), and almost all were MSM (419/426 or 98.4%).

136 The mean age was 32.4 years. University or post-graduate studies had been completed by 86% of

137 participants (365/426), and 91% were employed (389/426), which reflects the higher socioeconomic

138 status of patients who access private fee-for-service care.

139 Perfect adherence of 100% of doses taken in the last 30 days was reported by 52.1% (222/426), 95–

140 99% was reported by 26.6% (113/426), adherence of 90–94% was reported by 12.7% (54/426), and

141 adherence of <90% was reported by 8.7% (37/426) of patients.

142 Medical history was extracted from patient files and included time on ART, nadir CD4 count,

143 history of opportunistic infections (OIs), current and past ART medications and regimen changes,

144 viral load suppression, and CD4 recovery. Various sociodemographic and clinical factors and their

145 association with self-reported adherence to ART at ≥95% are reported in Table 1.

146 *Patient demographic and clinical characteristics*

147 *Demographics*

148 There is evidence to suggest that low education level is associated with non-adherence (OR = 0.20,

149 $P = 0.031$). There was no strong evidence of associations between employment/profession or age and

150 adherence.

151 Patients working in the Business Process Outsourcing (BPO) sector had lower adherence than other

152 professions; this may be due to the varying shift times worked by call centre agents in this sector.

153 Health workers had the highest adherence of any profession, followed by self-employed individuals.

154 However, overall, there was no strong evidence of association between employment/profession and

155 adherence.

156 Relationship status appears to be an important factor in ART adherence. Of the 27.9% of subjects

157 (119/426) who were in a relationship, most were in a serodiscordant relationship in which their

158 primary partner was HIV negative. Those in serodiscordant partnerships had improved odds of

159 adherence to ART compared with individuals who were not in a relationship (OR = 2.49). The

160 evidence suggests that being in seroconcordant relationships (both HIV positive) and disclosure of

161 HIV status to a trusted person may be also be factors that improve adherence; however, the sample

162 size in this study was insufficient to reach these conclusions with confidence.

163 *Adherence and viral suppression*

164 Self-reported adherent patients were more likely to be virally suppressed (OR = 3.1, $P = 0.016$).

165 *Time on ART and virological failure*

166 Having been on ART for a longer time led to decreased adherence (0–6 months: OR = 1.00; 6

167 months−1year: OR = 0.36; 1–2 years: OR = 0.43; 2–4 years: OR = 0.32; ≥4 years: OR = 0.25; $P =$

168 0.013), which indicates that patients may be experiencing treatment fatigue over time.

169   In total, 27.9% of patients (119/426) had changed their ART medications at least once. Of those

170   who changed regimens, 17.7% (21/119) had to change due to virological failure, whereas the

171   remaining 98 people changed for other reasons such as intolerance/side-effects or depression

172   worsened by efavirenz (EFV). Only 7.5% of patients (32/426) were on second-line lopinavir/ritonavir

173   (LPV/r) or multiple resistance ART regimens, whereas 92.5% (394/426) were on efavirenz,

174   nevirapine, or rilpivirine-based first-line ART regimens.

175   *CD4 and opportunistic infections history*

176   Most patients had a nadir CD4 count in the range of 200–350 cells/mm^3, indicating that they were

177   diagnosed and started on ART before disease progression to AIDS. However, 74 patients (17.4%) had

178   nadir CD4 count <50 cells/mm^3, indicating that they did not receive HIV diagnosis and treatment until

179   they were already severely immune-compromised. Only 51.5% (206/400) of patients who had a nadir

180   CD4 count <500 cells/mm^3 had reached CD4 recovery back to levels <500 cells/mm^3.

181   History of OI was common, with 61% of patients (260/426) having one or more potential OIs

182   recorded in their complete medical history. Pnuemocystis pneumonia (PCP) history was recorded in

183   the medical history of 6% of patients (27/426), and 5% had a history of thrush (20/426). Hepatitis B at

184   11% (46/426) and tuberculosis (TB) history at 18% (76/426) are similar to the overall population rates

185   of these diseases, which are endemic to the Philippines.[19,20] Hepatitis C prevalence was 0.7% in our

186   cohort (3/426), which is also similar to the general population rate.[19] Over 13% of patients (57/426)

187   had a history of syphilis and 39% (166/426) had had another sexually transmissible infection (STI).

188   There was no evidence of an association between ART adherence and nadir CD4, CD4 recovery, or

189   OI history.

190   *Risk behaviours*

191   The association between risk behaviours and ART adherence is outlined in Table 2.

192   *Sexual partners and condom use*

193   The mean number of sex partners for participants in the last 6 months was 2.73. Among participant

194   21.8% reported zero partners (93/426), 32.2% reported one partner (137/426), 23.2% reported

195   between two and nine partners (99/426), and 4.2% reported >10 partners (18/426), whereas 20.9%

196   (89/426) of participants did not provide an answer on the questionnaire. Only 6% (25/426) of the

197   patients reported having ever engaged in transactional sex, and of those, only two participants had had

198   transactional sex within the last 6 months. In the study population, 41.3% (176/426) reported they

199   always use condoms and 35.4% (151/426) use them some of the time or most of the time. This

200   inconsistent condom use was associated with non-adherence to ART (OR = 0.48, $P = 0.007$);

201   however, individuals who reported never using condoms did not have reduced odds of ART

202   adherence.

203   *Drug and alcohol use*

204   In our study population, 9.4% (40/426) used 'shabu' (methamphetamine hydrochloride), 8.0%

205   (34/426) used cannabis, 4.5% (19/423) used prescription drugs for non-medical use, and 1.4% (6/426)

206   used inhalants (e.g. 'rugby' or 'poppers') within the last 3 months, and 0.7% (3/426) of respondents

207   did not complete the substance use portion of the questionnaire. Injecting drug users (IDU) were

208   12.2% (52/426) of the study population; 52 who had ever injected drugs and 28 who had done so

209   within the last 3 months. Among IDUs, the odds of ART adherence were lower (IDU ever OR = 0.46,

210    $P = 0.015$; IDU in last 3 months OR = 0.38, $P = 0.019$). Only two individuals reported ever having

211   shared needles for injecting drugs. There was no association between adherence and non-injecting

212   drug use.

213   Although 30.5% (130/426) of patients abstained from alcohol, 37.3% (159/426) engaged in heavy

214   episodic drinking in the last 30 days. Problem drinking, defined as two or more episodes of heavy

215   episodic or 'binge' drinking (>five drinks) in the last month or >14 drinks per week on average,[21,22]

216   was prevalent in 13.4% (57/426) of the study population. Alcohol use did not have an association with

217   ART adherence.

218   *Quality of life*

219   The WHO HIV-QL31 scores QOL in six domains, a maximum of 20 points per domain and a total

220   score of 120. The mean for each of the six domains and the total WHO HIV-QL31 score are as

221   follows: Physical 15.21; Psychological 15.04; Level of Independence 15.54; Social Relationships

222   15.01; Environmental 13.43; and Spirituality 14.44. The domain with the lowest overall score was

223   Environment, which measures aspects such as safety and security; access to health care; financial

224   resources; opportunities for learning and for leisure; and physical environment

225   (pollution/noise/traffic/climate).[23]

226   The mean QOL score in the cohort was 88.68 (95% CI 87.46–89.89). Just under half (46.5%) of the

227   426 participants had an overall QOL score of ≥90, which represents a high QOL, and 52.3% percent

228   had a medium QOL with a score between 60 and 89. Only five patients (1.3%) had a QOL score <60.

229   One patient did not complete the QOL questionnaire. There was no significant association between

230   ART adherence and overall QOL (Table 2) or individual QOL domains (data not shown).

231   *Knowledge of HIV*

232   There was evidence of an association between knowledge of HIV, as scored on a 16-item

233   questionnaire, and ART adherence. There is an association between scoring 80% and 89% on the HIV

234   knowledge questionnaire and lower adherence (OR = 0.49, $P = 0.044$). This association does not hold

235   for those scoring >90% and the reason for the association is unclear, warranting further investigation.

236 *Adherence/reasons for missing medication*

237   There were 228 study participants who reported having missed medications at any point in the past;

238 the reasons they reported for ever missing medications are detailed in Figure 1. The most common

239 reasons for missing medications were that that the patient was busy, they forgot, fell asleep, was away

240 from home, or had a change in their daily routine. Stigma is also a factor affecting adherence, as 44%

241 of patients who had skipped a pill at some point did so because they did not want to be seen taking

242 medications. Issues around side-effects, toxicity, and pill burden were the least likely contributors to

243 non-adherence.

244 *Multivariate logistic regression model for adherence to antiretroviral therapy*

245   In the final multivariate logistic regression model (Table 3), time on ART (adjusted OR (AOR) =

246 0.87 per year, $P = 0.027$ seroconcordant/serodiscordant relationship status ($P = 0.006$)), and

247 knowledge score ($P = 0.047$) were associated with ART adherence. Injection drug use and

248 inconsistent condom use (using condoms sometimes or most of the time) may also be related to

249 adherence, whereas the study sample may have been too small to evaluate these factors.

250 **Discussion**

251   Twenty-one percent (91/426) of the study participants reported suboptimal adherence. By

252 comparison, ~37% of patients globally report suboptimal adherence to ART,[17,24] and in the regional

253 Therapeutics Research, Education, and AIDS Training in Asia (TREAT Asia) cohort (which includes

254 a large treatment site in the Philippines), 32% of 1316 patients reported suboptimal adherence of

255 <100%.[11] As expected, self-reported adherent patients were more likely to be virally suppressed,

256 which indicates that patient self-report of adherence or non-adherence accurately reflects their pill-

257 taking behaviour.

258   The study found that people who had been on treatment longer were less likely to be adherent to

259 their ART. This finding is contrary to the TREAT Asia regional cohort study, which found 26% of

260 patients self-reported suboptimal adherence levels during their first 6 months of treatment, and that

261 adherence improved over time from initiation to 24 months.[11] These contradictory findings warrant

262 further investigation. Reasons for non-adherence in this study were largely situational factors, habits,

263 and routines, whereas clinical issues such as side-effects and pill burden were less likely to impact

264 adherence in this population.

265   Condom use in this study population was comparable to the general MSM population in the

266 Philippines – 41.3% (146/405) of the sexually active SHIP population study participants always use

267 condoms and 35.5% (151/405) use condoms most or some of the time, whereas the 2013 surveillance

268 data showed 40.7% condom use at last anal sex among MSM.[8,25] Inconsistent condom use (using

269 condoms sometimes or most of the time) may be associated with ART non-adherence, which suggests

270 that motivating factors and abilities that enable a patient to adhere to ART could also be the same

271 factors that lead to consistent condom use. The average total number of sex partners in the last 6

272 months was 2.14, which is lower than has been reported in other surveillance of MSM in the

273 Philippines;[8,25] this may indicate that MSM reduce their sexual activity after becoming HIV positive

274 and starting ART, a question that warrants further investigation.

275   Relationship status appears to be an important factor in ART adherence. Patients in serodiscordant

276 relationships were more likely to adhere to ART. The data suggest that being in a relationship,

277 whether seroconcordant or serodiscordant, is better than being single when it comes to ART

278 adherence, and that disclosure of one's HIV-positive status to a trusted person can also lead to better

279 outcomes. These findings emphasise the important role of partner, family and social support for HIV

280 patients in order to achieve good clinical outcomes.

281   Another key finding in this study is that the study participants used drugs and alcohol at rates five-

282 to 10-fold higher than the general population. In the Philippines general population, 44.7% of males

283 abstain from alcohol and 3.5% of males engage in heavy episodic drinking,[26] whereas in our study

284 population, only 30.5% abstained and 37.3% had engaged in heavy episodic drinking in the last 30

285 days. According to the United Nations Office on Drugs and Crime, 1.1% of Filipinos use 'shabu'

286 (methamphetamine hydrochloride) and 1.6% use cannabis.[27] In our study population, 9.9% had used

287 'shabu' and 7.7% used cannabis within the last 3 months. Methamphetamine use is strongly

288 associated with high-risk sexual behaviour and HIV acquisition,[28] and is commonly used by MSM in

289 chemsex or 'Partee 'n' Play' activities. Compounding these risks, evidence-based HIV prevention

290 services are not widely available in the Philippines – condom distribution is restricted,[29,30] pre- and

291 post-exposure prophylaxis are not widely available, except through very limited pilot projects, and

292 syringe exchange is illegal under the current administration's interpretation of the Philippines'

293 Dangerous Drugs Act of 2002.

294 *Limitations*

295   This study is limited by several factors. First, adherence and risk behaviours were self-reported, and

296 the responses are subject to social desirability bias. However, adherence was strongly associated with

297 viral load suppression, and risk behaviours were not significantly lower than the general population

298 (and in many cases much higher), which suggests that the self-report method was generally accurate.

299 Furthermore, the generalisability of study data from the SHIP clinic population is limited. Due to the

300 higher socioeconomic status and education levels of the SHIP clinic patients, and due to the fact that it

301 is a fee-for-service clinic, the cohort may not be representative of MSM in the Philippines more

302 broadly. Apart from employment, education, and high HIV knowledge levels, other demographic

303 factors (age, clinical outcomes, risk profile) align with other published data on MSM and people

304 living with HIV from the country.[7,8,25,31] Ongoing follow up of the SHIP Connect for Life study cohort

305 will provide further details about incidence of OIs, retention in care, and ART adherence.

306   **Conclusions**

307   This study provides an in-depth analysis of demographic, clinical, and behavioural characteristics

308   of MSM living with HIV in the Philippines, which can improve understanding of the country's

309   epidemic and may be used to inform tailored prevention and treatment interventions.

310   Factors found to be associated with adherence to HIV treatment were time on ART, being in a

311   serodiscordant relationship in which the person's main partner is HIV negative, and HIV knowledge

312   level.

313   The issue of treatment fatigue warrants further investigation and should be addressed through

314   implementation of tailored adherence interventions. Clinicians and other service providers should

315   prioritise counselling and interventions to improve family and social support for HIV patients. There

316   is also an unexplored opportunity for harm-reduction interventions among HIV-positive and HIV-

317   negative MSM who use drugs and alcohol.

327   **References**

328   <jrn>1 Gangcuangco LMA. HIV crisis in the Philippines: urgent actions needed. Lancet Public Health 2019;

329   4(2): e84. doi:10.1016/S2468-2667(18)30265-2</jrn>

330   <eref>2 Geronimo JY. WHO: PH has fastest growing HIV epidemic in the world. Rappler, 20 May 2015.

331   Available online at: http://www.rappler.com/nation/93839-who-ph-response-hiv [verified 27 December

332   2020].</eref>

333   <jrn>3 The Lancet. Losing the fight against HIV in the Philippines. Lancet 2017; 390(10095): 626.

334   doi:10.1016/S0140-6736(17)32211-0</jrn>

335   <eref>4 Department of Health Philippines, Epidemiology Bureau. HIV/AIDS and ART registry of the

336   Philippines, March 2019. 2019. Available online at:

337   https://doh.gov.ph/sites/default/files/statistics/HIV_STAT_2019MAR.pdf [verified 27 December 2020].</eref>

338 <eref>5 Joint United Nations Programme on HIV/AIDS (UNAIDS). UNAIDS data 2017. 2017. Available
339 online at: http://www.unaids.org/sites/default/files/media_asset/20170720_Data_book_2017_en.pdf pdf
340 [verified 27 December 2020].</eref>

341 <eref>6 Joint United Nations Programme on HIV/AIDS (UNAIDS). 2014 global AIDS response progress
342 reporting – country progress report: Philippines. 2014. Available online at:
343 https://www.unaids.org/sites/default/files/country/documents/PHL_narrative_report_2014.pdf [verified 27
344 December 2020].</eref>

345 <eref>7 Department of Health Philippines, Epidemiology Bureau. 2015 integrated HIV behavioral and serologic
346 survey (IHBSS) fact sheets. 2016. Available online at:
347 https://doh.gov.ph/sites/default/files/publications/Philippines_2015_IHBSS_Fact_Sheets_Nov2017_22JUN2016
348 .pdf [verified 27 December 2020].</eref>

349 <eref>8 National Epidemiology Center, Department of Health Philippines. 2013 integrated behavioral and
350 serologic surveillance (IHBSS) report. 2014. Available online at:
351 https://doh.gov.ph/sites/default/files/publications/2013IHBSSFinalReport%28XII.2014%29.pdf [verified 27
352 December 2020].</eref>

353 <jrn>9 de Lind van Wijngaarden JW, Ching AD, Settle E, van Griensven F, Cruz RC, Newman PA. 'I am not
354 promiscuous enough!': exploring the low uptake of HIV testing by gay men and other men who have sex with
355 men in Metro Manila, Philippines. PLoS One 2018 13(7): e0200256.</jrn>

356 <eref>10 Leyritana K, Alejandria M, Tenorio A, Salvaña EMT. 1489. The evolving epidemiology of people
357 living with HIV in a developing country in the midst of an epidemic: a descriptive cohort. [Poster Abstract
358 Session] 2013. Available online at: https://idsa.confex.com/idsa/2013/webprogram/Paper40015.html [verified
359 27 December 2020].</eref>

360 <jrn>11 Jiamsakul A, Kumarasamy N, Ditangco R, Li PCK, Phanuphak P, Sirisanthana T, et al. Factors
361 associated with suboptimal adherence to antiretroviral therapy in Asia. J Int AIDS Soc 2014; 17: 18911.
362 doi:10.7448/IAS.17.1.18911</jrn>

363 <eref>12 World Health Organization. External review of the national health sector response to HIV and
364 sexually transmitted infections 2013: Republic of the Philippines. 2015. Available online at:
365 http://iris.wpro.who.int/bitstream/handle/10665.1/11217/9789290617068_eng.pdf [verified 27 December
366 2020].</eref>

367 <jrn>13 Restar A, Nguyen M, Nguyen K, Adia AC, Nazareno J, Yoshioka E, et al. Trends and emerging
368 directions in HIV risk and prevention research in the Philippines: a systematic review of the literature. PLoS
369 One 2018; 13(12): e0207663. doi:10.1371/journal.pone.0207663</jrn>

370 <jrn>14 Bangsberg DR, Hecht FM, Charlebois ED, Zolopa AR, Holodniy M, Sheiner L, et al. Adherence to
371 protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000;
372 14(4): 357–66. doi:10.1097/00002030-200003100-00008</jrn>

373   <jrn>15 Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease

374   inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133(1): 21–30.

375   doi:10.7326/0003-4819-133-1-200007040-00004</jrn>

376   <jrn>16 Ammassari A, Trotta MP, Shalev N, Marconi P, Antinori A. Beyond virological suppression: the role

377   of adherence in the late HAART era. Antivir Ther 2012; 17(5): 785–92. doi:10.3851/IMP2084</jrn>

378   <jrn>17 Bezabhe WM, Chalmers L, Bereznicki LR, Peterson GM. Adherence to antiretroviral therapy and

379   virologic failure: a meta-analysis. Medicine (Baltimore) 2016; 95(15): e3361.

380   doi:10.1097/MD.0000000000003361</jrn>

381   <jrn>18 Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can

382   lead to viral suppression. Clin Infect Dis 2006; 43(7): 939–41. doi:10.1086/507526</jrn>

383   <eref>19 Hepatitis Society of the PHilippines. Patient resources. 2020. Available online at:

384   https://hsp.org.ph/patientresources.php [verified dd mm yyyy].</eref>

385   <jrn>20 Abdelghaffar Hibah N, Hasan H-E. Prevalence of latent tuberculosis infection among multinational

386   healthcare workers in Muhayil Saudi Arabia. Egypt J Bronchol 2015; 9(2): 183–7. doi:10.4103/1687-

387   8426.158078</jrn>

388   <eref>21 National Institute on Alcohol Abuse and Alcoholism. Drinking levels defined. 2011. Available online

389   at: https://www.niaaa.nih.gov/alcohol-health/overview-alcohol-consumption/moderate-binge-drinking [verified

390   27 December 2020].</eref>

391   <jrn>22 Carliner H, Mauro PM, Brown QL, Shmulewitz D, Rahim-Juwel R, Sarvet al, et al. Key substance use

392   and mental health indicators in the United States. Drug Alcohol Depend 2017; 170: 51–8.

393   doi:10.1016/j.drugalcdep.2016.10.042</jrn>

394   <eref>23 World Health Organization (WHO). WHOQOL-HIV instrument user's manual: scoring and coding

395   for the WHOQOL-HIV instruments. 2002. Available online at:

396   https://apps.who.int/iris/bitstream/handle/10665/77776/WHO_MSD_MER_Rev.2012.03_eng.pdf?sequence=1&

397   isAllowed=y [verified 27 December 2020].</eref>

398   <jrn>24 Ortego C, Huedo-Medina TB, Llorca J, Sevilla L, Santos P, Rodríguez E, et al. Adherence to highly

399   active antiretroviral therapy (HAART): a meta-analysis. AIDS Behav 2011; 15(7): 1381–96.

400   doi:10.1007/s10461-011-9942-x</jrn>

401   <jrn>25 Gangcuangco LMA, Tan ML, Berba RP. Prevalence and risk factors for HIV infection among men

402   having sex with men in Metro Manila, Philippines. Southeast Asian J Trop Med Public Health 2013; 44(5):

403   810–7.</jrn>

404   <eref>26 World Health Organization (WHO). WHO global alcohol report: Philippines. 2014. Available online

405   at: http://www.who.int/substance_abuse/publications/global_alcohol_report/profiles/phl.pdf [verified 27

406   December 2020].</eref>

407   <eref>27 United Nations Office of Drugs and Crime. Prevalence of drug use in the general population: national

408   data. 2016. Available online at:

409 https://www.unodc.org/wdr2018/prelaunch/1.2_Prevalence_of_drug_use_in_the_general_population_-

410 _national_data.xls [verified 27 December 2020].</eref>

411 <jrn>28 Hoenigl M, Chaillon A, Moore DJ, Morris SR, Smith DM, Little SJ. Clear links between starting

412 methamphetamine and increasing sexual risk behavior: a cohort study among men who have sex with men. J

413 Acquir Immune Defic Syndr 2016; 71(5): 551–7. doi:10.1097/QAI.0000000000000888</jrn>

414 <eref>29 Human Rights Watch. Fueling the Philippines' HIV epidemic: government barriers to condom use by

415 men who have sex with men. 2016. Available online at:

416 https://www.hrw.org/sites/default/files/report_pdf/philippines1216_web.pdf [verified 27 December

417 2020].</eref>

418 <jrn>30 Dombrowski JC, Dorabjee J, Strathdee SA, Diego S. Atrocity in the Philippines: how Rodrigo

419 Duterte's war on drug users may exacerbate the burgeoning HIV epidemic. J Acquir Immune Defic Syndr 2017;

420 76(1): 23–5. doi:10.1097/QAI.0000000000001464</jrn>

421 <eref>31 Samonte GMJ, Belimac JGB, Feliciano JS. Philippine estimates of the most at-risk population and

422 people living with HIV. 2011. Available online at:

423 https://doh.gov.ph/sites/default/files/publications/2011PLHIVandMARPEstimates.pdf [verified 27 December

424 2020].</eref>

425 **Fig. 1.**   Reasons for missing medication (*n* = 228).

426

427

428 ## Table 1.   Patient characteristics

429 OR, odds ratio; CI, confidence interval; ART, antiretroviral therapy

Patient characteristics	Total	Adherent ≥95%	Non-adherent <95%

	(n = 426)		(n = 335)		(n = 91)		Crude OR (95% CI)	P-value
	n	(%)	n	(%)	n	(%)		
Gender								
Male	425	99.77	334	78.59	91	21.41	–	
Female	1	0.23	1	100.00	0	0.00	–	
Age (years)								
18–24	19	4.46	17	89.47	2	10.53	1.00	
25–29	119	27.93	95	79.83	24	20.17	0.47 (0.10–2.16)	
30–39	245	57.51	188	76.73	57	23.27	0.39 (0.09–1.73)	0.498
≥40	43	10.09	35	81.40	8	18.60	0.51 (0.10–2.69)	
Education								
Elementary or less	10	2.35	4	40.00	6	60.00	0.20 (0.05−0.72)*	
High School/Vocational	19	4.46	15	78.95	4	21.05	1.11 (0.36–3.44)	
College/University	316	74.18	244	77.22	72	22.78	1.00	0.010*
Post-Graduate	49	11.50	44	89.80	5	10.20	2.60 (0.99–6.79)	
Unknown/Did not report	32	7.51	28	87.50	4	12.50	2.07 (0.70–6.08)	
Employment								
Business Process Outsourcing (BPO)	88	20.66	66	75.00	22	25.00	1.00	
Self-Employed/Other	38	8.92	34	89.47	4	10.53	2.83 (0.90–8.89)	
Health Worker	16	3.76	15	93.75	1	6.25	5.00 (0.62–40.06)	0.406
Professional[A]	234	54.93	182	77.78	52	22.22	1.17 (0.66–2.07)	
Student	13	3.05	10	76.92	3	23.08	1.11 (0.28–4.41)	
Unemployed	37	8.69	28	75.68	9	24.32	1.04 (0.42–2.53)	
Sexual orientation								
Bisexual	128	30.05	96	75.00	32	25.00	1.00	
Heterosexual	7	1.64	6	85.71	1	14.29	2.00 (0.23–17.25)	
Homosexual	290	68.08	232	80.00	58	20.00	1.33 (0.81–2.18)	0.467
Pansexual	1	0.23	1	100.00	0	0.00	–	
Civil status								
Married/Common-law partner	21	4.93	19	90.48	2	9.52	1.00	
Single	404	94.84	315	77.97	89	22.03	0.47 (0.11–2.10)	0.282
Unknown/Did not report	1	0.23	1	100.00	0	0.00	–	
Serodiscordant								
Not in a relationship	262	61.50	199	75.95	63	24.05	1.00	
Seroconcordant relationship (both HIV+)	48	11.27	41	85.42	7	14.58	1.85 (0.79–4.34)	0.030*
Serodiscordant relationship (partner is HIV−)	71	16.67	63	88.73	8	11.27	2.49 (1.13–5.48)*	
Unknown/Did not report	45	10.56	32	71.11	13	28.89	0.78 (0.39–1.58)	

Disclosure of HIV status to family/friend								
Disclosed	137	32.16	113	82.48	24	17.52	1.00	
Not disclosed	207	48.59	155	74.88	52	25.12	0.63 (0.37–1.09)	
Unknown/Did not report	82	19.25	67	81.71	15	18.29	0.95 (0.47–1.93)	0.181
Time on ART, years (mean)	2.77 years (95% CI 2.58–2.96)		2.61 (2.40–2.82)		3.35 (2.90–3.79)			
0–6 months	46	10.80	42	91.30	4	8.70	1.00	
6 months – 1 year	38	8.92	30	78.95	8	21.95	0.36 (0.10–1.3)	
1–2 years	83	19.48	68	81.93	15	18.07	0.43 (0.13–1.39)*	
2–4 years	162	38.03	125	77.16	37	22.84	0.32 (0.11–0.96)*	0.078
>4 years	97	22.77	70	72.16	27	27.84	0.25 (0.08–0.75)*	
Nadir CD4 (cells/mm^3) (Mean)	245 (95% CI 229–260)		246 (227–263)		244 (212–275)			
0–200	163	38.26	132	80.98	31	19.02	1.00	
200–499	237	54.76	179	75.53	58	24.47	0.72 (0.44–1.18)	0.065
500+	26	6.93	24	92.31	2	7.69	2.82 (0.63–12.56)	
Viral Suppression								
Undetectable	257	92.45	207	80.54	50	19.46	3.11 (1.24–7.77)	0.020*
Detectable (>500 copies)	21	7.55	12	57.14	9	42.86	1.00	

430   *Adherence is self-reported over the last 30 days.

431   [A]'Professional' is a broad category that includes patients who work as corporate or government employees, and

432   workers in the education, IT, science, engineering, media, and sales and marketing sectors.

433   **Table 2.**   **Association between risk behaviours and antiretroviral therapy adherence**

434   OR, odds ratio; CI, confidence interval; N/A, not applicable

	Total (n = 426)		Adherent ≥95% (n = 335)		Non-adherent <95% (n = 91)		Crude OR (95% CI)	P-value
	n	(%)	n	(%)	n	(%)		
Condom usage in last 6 months								
Always	176	41.31	146	82.95	30	17.05	1.00	
Sometimes/Most of the time	151	35.45	106	70.20	45	29.80	0.48 (0.29–0.82)*	0.043*
Never	78	18.31	66	84.62	12	15.38	1.13 (0.54–2.35)	
N/A (not sexually active)	21	4.93	17	80.95	4	19.05	0.87 (0.27–2.78)	
Transactional sex								
Never had transactional sex	399	93.66	314	78.70	85	21.30	1.00	0.662
Ever had transactional sex	25	5.87	20	80.00	5	20.00	1.08 (0.39–2.97)	

Variable	N	%	n	%	n	%	OR (95% CI)	P-value
Unknown/Refused	2	0.47	1	50.00	1	50.00	0.27 (0.02–4.37)	
Drug use in last 3 months								
No	356	83.57	282	79.21	74	20.79	1.00	0.519
Yes	70	16.43	53	75.71	17	24.29	0.82 (0.45–1.50)	
Injection drug use ever								
No	374	87.79	301	80.48	73	19.52	1.00	0.018*
Yes	52	12.21	34	65.38	18	34.62	0.46 (0.25–0.86)*	
Heavy alcohol use								
No	363	86.43	289	79.61	74	20.39	1.00	0.201
Yes	57	13.57	41	71.93	16	28.07	0.66 (0.35–1.23)	
Quality of life (QOL)	88.68 (95% CI 87.46–89.89)		89.45 (88.13–90.76)		85.85 (82.97–88.73)			
High (90–120)	183	46.45	148	80.87	35	19.13	1.00	
Medium (60–89)	206	52.28	159	77.18	47	22.82	0.80 (0.49–1.31)	0.427
Low (0–59)	5	1.27	3	60.00	2	40.00	0.35 (0.06–2.20)	
HIV knowledge Score (mean, %)	85.01% score (95% CI 83.74–86.29)		85.01% (83.53–86.49)		85.03% (82.54–87.51)			
<80	95	22.35	80	84.21	15	15.79	1.00	
80–89	163	38.35	118	72.39	45	27.61	0.49 (0.26–0.94)*	0.044*
≤90	167	39.29	136	81.44	31	18.56	0.82 (0.42–1.62)	

Table 3. Multivariate logistic regression analysis of factors associated with antiretroviral therapy (ART) adherence

OR, odds ratio; CI, confidence interval; N/A, not applicable

Variable	Adjusted OR	95% CI	P-value
Education			
Elementary or less	0.42	(0.10–1.75)	
High School/Vocational	1.16	(0.36–3.82)	
College/University	1.00		0.084
Post-Graduate	2.40	(0.87–6.63)	
Unknown	2.57	(0.81–8.16)	
Serodiscordant			
N/A not in a relationship	1.00		
Seroconcordant relationship (both HIV+)	2.37	(0.95–5.93)	0.006*
Serodiscordant relationship (partner is HIV−)	3.19	(1.39–7.35)	
Unknown	0.81	(0.37–1.79)	
Time on ART, years	0.87	(0.77–0.98)	0.027*

Nadir CD4 (cells/mm^3)

0–200	1.00		
200–499	0.78	(0.46–1.33)	0.1334
500+	2.87	(0.60–13.61)	

Condom usage (in last 6 months)

Always	1.00		
Sometimes/Most of the time	0.50	(0.28–0.89)	
Never	0.81	(0.24–2.75)	0.103
N/A (not sexually active)	0.94	(0.43–2.06)	

Injection drug use (in last 3 months)	0.54	(0.27–1.09)	0.090

HIV Knowledge Score (mean, %)

<80	1.00		
80–89	0.47	(0.23–0.94)	0.047*
≤90	0.81	(0.39–1.67)	

438

439

440